1 / 74

Australia Antibacterial (Antibiotics) Drugs Market Analysis Sample Report

This report presents a strategic analysis of the Australia Antibacterial (Antibiotics) Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. To get a detailed report, contact us at - info@insights10.com

Insights4
Download Presentation

Australia Antibacterial (Antibiotics) Drugs Market Analysis Sample Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A sample report on Australia Antibacterial (Antibiotics) Drugs Market Analysis

  2. This report presents a strategic analysis of the Australia Antibacterial (Antibiotics) Drugs Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about (Antibiotics) Drugs Market, and offers unmatched value, accuracy, and expert insights. the Australia Antibacterial

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 07-14 1. Antibiotic Market Overview 1.1. Overview 1.2. Australia Overview 1.3. Economic Overview: Australia 1.4. Antibiotic Market in Australia 1.5. Healthcare Scenario in Australia 1.6. Mergers and Acquisitions 15-20 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 2.2.Market Segmentation 2.2.1. By Class of Antibiotic 2.2.2. By Type of Infection 4 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 2.2.3. By Route of Administration 21-25 3. Market Dynamics 3.1. Market Growth Drivers 3.2. Market Restraints 26-35 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. GSK 4.2.2. Pfizer 4.2.3. Novartis 4.2.4. Johnson and Johnson 4.2.5. Abbott 4.2.6. Merck and Co. 5 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  6. Table of Content CONTENT PG. NO. 4.2.7. Aurobindo Pharma 4.2.8. Bayer HealthCare 4.2.9. Eli Lilly 4.2.10. Sun Pharmaceuticals 36-41 6. Pricing & Reimbursement 6.1. Key Pricing Trends 6.2.Pricing 6.3.Reimbursement Regulation in Australia 6.4. Reimbursement Process 42-74 7. Methodology & Scope 6 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  7. Australia Antibacterial (Antibiotics) Drugs Market Analysis 1. Market Overview

  8. 1.1 Antibiotics Overview Antibiotics are medications that cure bacterial illnesses by either bactericidal (killing the bacteria) or bacteriostatic (preventing the bacteria from spreading) action ▪ They are available in different forms, including tablets, capsules, liquids you can drink, creams, lotions, sprays, drops, and injections ▪ Based on their chemical structure, antibiotics are categorized into distinct classes, and each class frequently has a different effect on the body and may be effective against a different bacterial species ▪ Here are the major classes of antibiotics: Class Antibiotic Marketed Formulations Penicillins Amoxicillin Amoxil Cephalosporins Cefalexin Keflex Aminoglycosides Gentamicin Genoptic Tetracyclines Doxycycline Vibramycin Macrolides Erythromycin Ery-Tab Fluoroquinolones Ciprofloxacin Cipro

  9. 1.1 Antibiotics Market in the World Australia Market ~$xx Bn Market Regional Analysis ➢ Africa: $_ _ ➢ APAC: $_ _ ➢ Europe: $_ _ ➢ LATAM: $_ _ ➢ Middle East: $_ _ ➢ North America: $_ _ Illustrative Illustrative 9 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  10. 1.2 Australia Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ $1675.42 Bn Is the Gross Domestic Product of Australia in 2022 26.4 Mn Population of Australia in 2023 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 81 years Is the life expectancy at birth in Australia in 2021 10.7% Of Australia’s GDP was spent on healthcare in 2021 Illustrative Illustrative 10 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  11. 1.3 Economic Overview: Australia Population of Australia, (2020-2030) GDP of Australia, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 55-64 65+ Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 11 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  12. 1.4 Statistics at a Glance: Antibiotic Market in Australia Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Australia ▪ $1 Bn+ Annual antibiotic sales in Australia 324K Hospitalizations due to bacterial infections in Australia in 2020-21 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ $1.5 Bn+ Cost of antibiotic resistance to the Australian economy 11K Hospitalizations due to pneumonia, the most common bacterial infection in Australia Illustrative Illustrative 12 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  13. 1.5 Healthcare Scenario in Australia ➢ Australian citizens have access to a variety of medical treatments including hospital care under Australia's public healthcare system, known as Medicare ➢ Australians can choose to use private healthcare services in addition to the healthcare provided by public hospitals, where patients are typically treated for free or at a low fee ➢ Antibiotics prescribed in Australia may be subsidized through the Pharmaceutical Benefits Scheme as it is an essential medication ➢ Antibiotic stewardship programs in Australia aim to optimize the use of antibiotics to improve patient outcomes while reducing the spread of antibiotic resistance Illustrative Illustrative 13 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  14. 1.6 Mergers and Acquisitions in Australia Latest Deals in Australia Amount / Duration Company Name Type Year Key Pointers AcuraBio Ltd is one of Australia's most experienced biopharmaceutical CDMOs which offers services to both domestic and international clients ▪ Recombinant proteins, vaccines, and complex live biotherapeutics are all offered by AcuraBio, along with quality, price, and intellectual property assurances September, 2022 ▪ Acquisition - Dr. Glenn Haifer and Ampersand Capital Partners acquisition of Luina Bio Acquisition further strengthens provisions of biopharma for the APAC Region ▪ CSL acquisition of Vifor Pharma was led with a vision to expand delivery of Vifor products to patients globally with the help of its scale and R&D resources CSL is a global biotech which specializes in medicines to treat serious and rare diseases and vaccines Vifor Pharma is a global specialty pharmaceutical company with market dominance in iron deficiency, nephrology and cardio-renal therapies ▪ August, 2022 ▪ Acquisition $11.7 Bn ▪ CSL acquisition of Vifor Pharma Illustrative Illustrative 14 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  15. Australia Antibacterial (Antibiotics) Drugs Market Analysis 2. Market Size and Forecasting

  16. 2.1 Market size and forecasts (Excel and Methodology) Australia Antibacterial (Antibiotics) Drugs Market Forecast, 2022- 2030 Click on the icon to know the methodology and assumption XX Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX In this section you will get an understanding of the overall market, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 2023 2024 2025 2026 2027 2028 2029 2030 Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Australia Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 % of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Australia Market Size ($Bn) 61 74 84 87 91 95 99 106 Illustrative Illustrative 16 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  17. 2.2 Snapshot of Antibacterial (Antibiotics) Drugs Market Segmentation Class of Antibiotic Type of Infection By Route of Administration Penicillins Respiratory Infections Topical Cephalosporins Urinary Tract Infections Parenteral Sulfonamides Skin and Soft Tissue Infections Oral Quinolones Sexually Transmitted Infections Macrolides Others Others In this section you will get an understanding of the segmentations which will cover the Australia Antibacterial (Antibiotics) Drugs Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Illustrative Illustrative 17 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  18. 2.2.1 Market Segmentation: By Antibiotic Class Australia Antibacterial (Antibiotics) Drugs Market Share, By Antibiotic Class (2022) Penicillins are the most commonly used class of antibiotics in Australia ▪ Other commonly used classes include Cephalosporins and Quinolones ▪ Others Penicillins Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Macrolides In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Cephalosporins Sulfonamides Quinolones Illustrative Illustrative 18 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  19. 2.2.2 Market Segmentation: By Type of Infection Most common bacterial infection in Australia is pneumonia, a respiratory infection resulting in 11,000 hospitalizations per year ▪ Australia Antibacterial (Antibiotics) Drugs Market Share, By Type of Infection (2022) Urinary Tract Infections are the second most common bacterial infections resulting in 8,000 hospitalizations per year ▪ Others Sexually Transmitted Infections Respiratory Infections Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Skin and Soft Tissue Infections In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic Illustrative Illustrative ▪ Urinary Tract Infections 19 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  20. 2.2.3 Market Segmentation: By Route of Administration Australia Antibacterial (Antibiotics) Drugs Market Share, By Route of Administration (2022) Most common type of formulation for bacterial infection in Australia is oral antibiotics ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Topical In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Oral Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Parenteral Illustrative Illustrative 20 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  21. Australia Antibacterial (Antibiotics) Drugs Market Analysis 3. Market Dynamics

  22. 3.1 Market Growth Drivers 3.1.1 High prevalence of bacterial infections resulting in over 3,24,000 hospitalizations in year 2020-21 in Australia Tropical climate and high population density majorly contribute to the high prevalence of bacterial infections in Australia ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 22 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  23. 3.1 Market Growth Drivers (Continued) 3.1.2 Increased disposable incomes of people in Australia as well as government initiatives are making antibiotics more affordable for Australian population Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) provide subsidies for antibiotics in Australia ▪ Under the PBS, the cost of most antibiotics is less than $30 per script, driving the market growth ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 23 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  24. 3.1 Market Growth Drivers (Continued) 3.1.3 Increased antibiotic resistance due to overconsumption of antibiotics by people driving the need for new and more powerful antibiotics in Australia Antibiotic resistance is predicted to result in over 7,000 deaths and 100,000 hospitalizations in Australia each year driving the demand for new antibacterial therapeutics ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 24 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  25. 3.2 Market Restraints 3.2.2 Lack of innovation in the antibiotics market due to the high cost of research and development 3.2.3 Cost for approval of antibiotics in Australia is high 3.2.1 Regulatory requirements for antibiotics in Australia are stringent Government regulations aimed at preventing the overuse of antibiotics are dampening the growth of the antibiotics market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Estimated time and cost for developing an antibiotic in Australia is 15 years and $1Bn respectively Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Increase in antibiotic drug approval costs of 45% over a 10- year period from 2011 to 2022 has been reported in Australia ▪ ▪ ▪ ▪ ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ ▪ ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 25 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  26. Australia Antibacterial (Antibiotics) Drugs Market Analysis 4. Competitive Landscape

  27. 4.1 Major Market Share Revenue of Major players in the Australia Antibacterial (Antibiotics) Drugs Market ($ Mn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Company 10 In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ Company 9 Company 8 Company 7 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Company 6 Company 5 Company 4 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Company 3 Company 2 Company 1 Illustrative Illustrative 27 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  28. 4.2 Key Players in Australia Antibacterial (Antibiotics) Drugs Market Key Note: Here is the list of top 10 companies which will cover in the final report ▪ 1 6 GlaxoSmithKline Plc Merck and Co. Each company will have slides for ▪ Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials (As per availability) If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Illustrative Illustrative o o 2 7 Pfizer Aurobindo Pharma o o o 3 8 Novartis Johnson & Johnson o o o 4 9 Abbott Eli Lilly ▪ ▪ 10 5 Bayer HealthCare Sun Pharmaceuticals 28 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  29. 4.2.1 Glaxosmithkline Plc Solutions offered by GSK Founded in: 2000 ▪ Glaxo Smith Kline(GSK) is a global pharmaceutical company that is one among the largest pharmaceutical players in Australian Market ▪ New strategic investments have been announced by GSK in Australia to ensure capacity building, medicines access and sustainable growth ▪ Their products include therapeutics for the treatment of infectious diseases, respiratory ailments, etc ➢ Vaccines HQ: UK ➢ Diabetes Care Type: Private ➢ Respiratory Infections Revenue: $34.70 Bn ➢ Cardiovascular Diseases Website: www.gsk.com ➢ Consumer Healthcare Some of the antibiotics by GSK Recent Activity / Press Coverage Amoxicillin (Augmentin)) Ciprofloxacin (Cipro) May, 2023 — GSK presented preliminary positive results from the phase III trial of its 5-in-1 meningococcal ABCWY vaccine candidate Azithromycin (Zithromax) Fluticasone (Avamys) Sept, 2022 — GSK has entered into an exclusive license agreement with Spero Therapeutics for tebipenem pivoxil HBr, a late-stage antibiotic that may treat complicated urinary tract infections Clarithromycin (Biaxin) Dutasteride (Avodart) June, 2021 — GSK announced its strategy, outlook for growth, and plans to deliver a step-change in growth and performance over the next ten years driven by a high-quality vaccines and specialty medicines portfolio and late-stage pipeline Ceftriaxone (Rocephin) Amoxicillin (Amoxil) Illustrative Illustrative 29 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  30. 4.2.1 Glaxosmithkline Plc (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers GSK has acquired BELLUS for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion ▪ BELLUS is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough ▪ Acquisition $2 Bn April, 2023 Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough ▪ BELLUS Health Boston-based Affinivax was acquired by GSK to scale a potentially disruptive vaccine technology which will help prevent infectious disease This acquisition is aimed to address global health needs by developing innovative vaccines ▪ August, 2022 Acquisition $3.3 Bn ▪ This acquisition aligns with GSK’s strategy of building a robust portfolio of specialty medicines and vaccines. ▪ Affinivax Inc 30 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  31. 4.2.1 Glaxosmithkline Plc (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2023 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 31 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  32. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Antibiotic Drugs Recent Activity / Press Coverage Drugs Indications 32 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  33. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners 33 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  34. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers 34 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  35. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 35 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  36. Australia Antibacterial (Antibiotics) Drugs Market Analysis 5. Pricing & Reimbursement

  37. 5.1 Key Pricing Trends Here are some of the key pricing trends in the Australian antibiotic market: Government regulations : Changes in regulatory policies and pricing regulations can have a significant impact on the pricing of antibiotics ▪ Market Competition: The level of competition in the antibiotic market can influence pricing ▪ Research and Development Costs: Companies may factor in research and development expenses when determining the pricing strategy ▪ Supply chain costs: Factors such as manufacturing, distribution, and supply chain costs can contribute to the overall pricing of antibiotics ▪ International Pricing Comparisons: Companies may consider international pricing trends and benchmarks when setting prices for antibiotics in Australia ▪ Global Health Crisis: Events such as the COVID-19 pandemic can have ripple effects on pharmaceutical markets, potentially impacting pricing dynamics ▪ Illustrative Illustrative 37 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  38. 5.2 Pricing Pricing Comparison in Australian Antibiotic Market Company GSK Novartis AG Pfizer Abbott SKUs Amoxicillin 35.82 37.94 37.94 35.82 Azithromycin 45.99 45.57 45.99 45.99 Ciprofloxacin 35.57 35.57 35.57 35.57 Clarithromycin 45.49 45.57 45.49 45.49 Cephalexin 37.87 37.57 37.87 37.87 Doxycycline 38.71 38.57 38.71 38.71 Flucloxacillin 35.72 35.57 35.72 35.72 Illustrative Illustrative 38 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  39. 5.3 Reimbursement Regulation for Antibiotics in Australia The reimbursement scenario in Australia is governed by both public and private players and are as follows- Medicare: Medicare offers all Australians, regardless of their income, discounted or free healthcare. Patients with specific bacterial illnesses are typically paid for their antibiotic costs ▪ Private Insurance Coverage: Most private health insurance policies cover the cost of antibiotics. However, the amount of coverage that a patient receives will vary depending on the policy ▪ Concession Card Holders: Concession card holders may be eligible for additional reimbursement for antibiotics under Medicare. For example, some concession card holders may be eligible for a higher reimbursement for antibiotics that are listed on the Medicare Benefits Schedule ▪ Pharmaceutical Benefits Scheme (PBS): Antibiotics that are prescribed by a registered medical practitioner and listed on the PBS are eligible for reimbursement ▪ Illustrative Illustrative 39 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  40. 5.3 Reimbursement Regulation in Australia (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in Australia healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 40 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  41. 5.4 Reimbursement Process The reimbursement process in Australia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: MoH Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 41 A Sample Report on Australia Antibacterial (Antibiotics) Drugs Market Analysis I Confidential

  42. Australia Antibacterial (Antibiotics) Drugs Market Analysis 6. Methodology & Scope

  43. A division of

  44. Life-sciences Market Research Reports you can trust Insights10 is a healthcare focused market research firm founded with an aim of being an insights driven company in the data driven world and delivering actionable insights that can drive decision and strategy making process for businesses www.insights10.com www.insights10.com

  45. Get actionable insights to take informed business decisions A large database of over 30,000 syndicated market research reports in pharmaceuticals and healthcare sector at global, regional as well as country level. We also provide customized research reports tailor made to suit your needs www.insights10.com

  46. Elevate your business plans with in-depth market analysis and industry intelligence Our qualitative, acute, and result-oriented market research reports provide a comprehensive understanding of the business scenario and the latest trends related to the life-sciences market www.insights10.com

  47. Gain a competitive edge with Insights10's customized healthcare research solutions Whether you are looking to expand into new areas, develop new products, or take advantage of new opportunities we have reports to help you accelerate and improve your plans by identifying unique growth prospects. www.insights10.com

  48. Market Research Reports across various categories Pharma (Diseases & Drugs) Digital Health Medical Devices Healthcare Services OTC & Clinical Trials Rare Diseases Nutraceuticals www.insights10.com

  49. FEATURED REPORS Free Sample Reports across various categories www.insights10.com

  50. What makes us different? 30000+ Life science Market Research Reports 22000+ Country Specific Reports 2000+ 1200+ Reports Published Annually Rare & orphan Disease Reports

More Related